



## Table of Contents

Volume 102, Issue 8: August 2017

### Cover Figure

Image generated by [www.somersault1824.com](http://www.somersault1824.com).

### Editorials

- 1299** p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin  
*Iris Z Uras, Florian Bellutti and Veronika Sexl*
- 1301** Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?  
*Bruno C. Medeiros*

### Guideline Article

- 1304** Recommendations regarding splenectomy in hereditary hemolytic anemias  
*Achille Iolascon et al.*

### Articles

#### *Red Cell Biology & its Disorders*

- 1314** Extracellular glycine is necessary for optimal hemoglobinization of erythroid cells  
*Daniel Garcia-Santos et al.*

#### *Hemostasis*

- 1324** Patient-derived anti- $\beta$ 2GPI antibodies recognize a peptide motif pattern and not a specific sequence of residues  
*Philippe de Moerloose et al.*

#### *Platelet Biology & its Disorders*

- 1333** Risk of cardiovascular events and pulmonary hypertension following splenectomy – a Danish population-based cohort study from 1996-2012  
*Marianne Rørholt et al.*
- 1342** Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia  
*Douglas B. Cines et al.*

#### *Myeloproliferative Disorders*

- 1352** Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome  
*Sa A. Wang et al.*

#### *Chronic Myeloid Leukemia*

- 1361** Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib  
*Stein-Erik Gullaksen et al.*
- 1368** Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study  
*Delphine Rea et al.*



*Acute Myeloid Leukemia*

**1378** FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27<sup>Kip1</sup> in acute myeloid leukemia  
*Ines Peschel et al.*

**1391** Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia  
*Dimitrios Papaioannou et al.*

*Chronic Lymphocytic Leukemia*

**1401** Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells  
*Elena Tibaldi et al.*

*Non-Hodgkin Lymphoma*

**1413** Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium  
*Wendy B.C. Stevens et al.*

*Plasma Cell Disorders*

**1424** Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up  
*Ute Hegenbart et al.*

**1432** Longitudinal fluorescence *in situ* hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation  
*Maximilian Merz et al.*

**1439** Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation  
*Rajshekhhar Chakraborty et al.*

*Cell Therapy & Immunotherapy*

**1446** Tbet is a critical modulator of FoxP3 expression in autoimmune graft-*versus*-host disease  
*Shoba Amarnath et al.*

**1457** Shorter leukocyte telomere length is associated with higher risk of infections: a prospective study of 75,309 individuals from the general population  
*Jens Helby et al.*

## Letters to the Editor

Letters are available online only at [www.haematologica.org/content/102/8.toc](http://www.haematologica.org/content/102/8.toc)

**e282** Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways  
*Jin Han et al.*  
<http://www.haematologica.org/content/102/8/e282>

**e285** NRF2 mediates  $\gamma$ -globin gene regulation and fetal hemoglobin induction in human erythroid progenitors  
*Xingguo Zhu et al.*  
<http://www.haematologica.org/content/102/8/e285>

**e289** Absence of the spleen and the occurrence of primary red cell alloimmunization in humans  
*Dorothea Evers et al.*  
<http://www.haematologica.org/content/102/8/e289>

**e293** Myelodysplasia and liver disease extend the spectrum of RTEL1 related telomeropathies  
*Shirleny R. Cardoso et al.*  
<http://www.haematologica.org/content/102/8/e293>



- e297** E14a2 *BCR-ABL1* transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy  
*Simone Claudiani et al.*  
<http://www.haematologica.org/content/102/8/e297>
- e300** Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia  
*Bon Ham Yip et al.*  
<http://www.haematologica.org/content/102/8/e300>
- e305** Mutations in the 3' untranslated region of *NOTCH1* are associated with low CD20 expression levels in chronic lymphocytic leukemia  
*Tamara Bittolo et al.*  
<http://www.haematologica.org/content/102/8/e305>
- e310** Clinical and diagnostic relevance of *NOTCH2* and *KLF2* mutations in splenic marginal zone lymphoma  
*Yolanda Campos-Martín et al.*  
<http://www.haematologica.org/content/102/8/e310>
- e313** The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype  
*Carolina Schinke et al.*  
<http://www.haematologica.org/content/102/8/e313>
- e317** Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma  
*Isabel J.F. Hofman et al.*  
<http://www.haematologica.org/content/102/8/e317>
- e321** Dynamics of epigenetic age following hematopoietic stem cell transplantation  
*Friedrich Stölzel et al.*  
<http://www.haematologica.org/content/102/8/e321>

## Case Reports

Case Reports are available online only at [www.haematologica.org/content/102/8.toc](http://www.haematologica.org/content/102/8.toc)

- e324** JAK1 somatic mutation in a myeloproliferative neoplasm  
*Suzanne O. Arulogun et al.*  
<http://www.haematologica.org/content/102/8/e324>
- e328** p.Y317H is a new *JAK2* gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with *CALR* mutation  
*Laura Eder-Azanza et al.*  
<http://www.haematologica.org/content/102/8/e328>